Allworth Financial LP Increases Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP)

Allworth Financial LP grew its stake in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 2,117.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,078 shares of the company's stock after buying an additional 14,398 shares during the period. Allworth Financial LP's holdings in CRISPR Therapeutics were worth $593,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of CRSP. Highline Wealth Partners LLC purchased a new stake in shares of CRISPR Therapeutics in the 4th quarter valued at $39,000. Western Pacific Wealth Management LP boosted its stake in shares of CRISPR Therapeutics by 100.0% in the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company's stock valued at $39,000 after purchasing an additional 500 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in shares of CRISPR Therapeutics in the 3rd quarter valued at $40,000. Darwin Wealth Management LLC purchased a new stake in shares of CRISPR Therapeutics in the 3rd quarter valued at $43,000. Finally, Eastern Bank purchased a new stake in shares of CRISPR Therapeutics in the 3rd quarter valued at $70,000. Hedge funds and other institutional investors own 69.20% of the company's stock.

Insider Buying and Selling

In related news, CEO Samarth Kulkarni sold 15,000 shares of the stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $55.10, for a total transaction of $826,500.00. Following the sale, the chief executive officer now directly owns 181,540 shares of the company's stock, valued at approximately $10,002,854. This represents a 7.63 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 4.10% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Evercore ISI raised shares of CRISPR Therapeutics from an "in-line" rating to an "outperform" rating and upped their price objective for the company from $60.00 to $99.00 in a research note on Friday, February 14th. Royal Bank of Canada cut their price objective on shares of CRISPR Therapeutics from $53.00 to $48.00 and set a "sector perform" rating for the company in a research note on Wednesday, February 12th. StockNews.com upgraded shares of CRISPR Therapeutics to a "sell" rating in a report on Thursday, February 13th. Cantor Fitzgerald reiterated a "neutral" rating on shares of CRISPR Therapeutics in a report on Wednesday. Finally, JMP Securities reiterated a "market outperform" rating and set a $86.00 price target on shares of CRISPR Therapeutics in a report on Thursday, February 13th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat, CRISPR Therapeutics currently has a consensus rating of "Hold" and an average target price of $74.40.

CRISPR Therapeutics Stock Performance

Shares of CRISPR Therapeutics stock traded down $2.52 during trading on Friday, hitting $47.91. The company's stock had a trading volume of 2,671,174 shares, compared to its average volume of 2,550,435. The company has a fifty day simple moving average of $42.25 and a two-hundred day simple moving average of $46.04. The company has a market capitalization of $4.11 billion, a PE ratio of -10.96 and a beta of 1.67. CRISPR Therapeutics AG has a 52 week low of $36.52 and a 52 week high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. As a group, analysts predict that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.